---
figid: PMC6230982__fonc-08-00500-g0002
figtitle: Metabolic pathways involved in anticancer drug resistance
organisms:
- NA
pmcid: PMC6230982
filename: fonc-08-00500-g0002.jpg
figlink: /pmc/articles/PMC6230982/figure/F2/
number: F2
caption: Metabolic pathways involved in anticancer drug resistance in multiple myeloma
  (A), lung- and ovarian cancer (B), breast cancer (C), and melanoma (D). Metabolic
  enzymes that are associated with drug resistance are shown in purple. Metabolic
  inhibitors that can be used to target drug-resistant cancers are depicted in red.
  2-DG, 2-deoxyglucose; 2ME, 2-methoxyestradiol; 6-AN, 6-aminonicotinamide; ATP, adenosine
  triphosphate; BPTES, bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide;
  BSO, buthionine sulphoximine; FASN, fatty acid synthase; G6PDH, glucose-6-phosphate
  dehydrogenase; GCLC, glutamate-cysteine ligase; GLS, glutaminase; HK2, hexokinase
  2; I, complex I; II, complex II; III, complex III; IV, complex IV; LDHA, lactate
  dehydrogenase A; LDHB, lactate dehydrogenase B; mTOR, mammalian target of rapamycin;
  NQO1, NAD(P)H quinone dehydrogenase; PDH, pyruvate dehydrogenase complex; PDK1,
  pyruvate dehydrogenase kinase 1; PHGDH, 3-phosphoglycerate dehydrogenase; PPP, pentose
  phosphate pathway; R5P, ribose 5-phosphate; ROS, reactive oxygen species; SOD2,
  superoxide dismutase 2; SSP, serine synthesis pathway; TCA, tricarboxylic acid cycle;
  V, complex V; xCT, glutamate/cysteine xCT antiporter.
papertitle: The Influence of Metabolism on Drug Response in Cancer.
reftext: Esther A. Zaal, et al. Front Oncol. 2018;8:500.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9471678
figid_alias: PMC6230982__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6230982__F2
ndex: 24ab90f5-debd-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6230982__fonc-08-00500-g0002.html
  '@type': Dataset
  description: Metabolic pathways involved in anticancer drug resistance in multiple
    myeloma (A), lung- and ovarian cancer (B), breast cancer (C), and melanoma (D).
    Metabolic enzymes that are associated with drug resistance are shown in purple.
    Metabolic inhibitors that can be used to target drug-resistant cancers are depicted
    in red. 2-DG, 2-deoxyglucose; 2ME, 2-methoxyestradiol; 6-AN, 6-aminonicotinamide;
    ATP, adenosine triphosphate; BPTES, bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl
    sulfide; BSO, buthionine sulphoximine; FASN, fatty acid synthase; G6PDH, glucose-6-phosphate
    dehydrogenase; GCLC, glutamate-cysteine ligase; GLS, glutaminase; HK2, hexokinase
    2; I, complex I; II, complex II; III, complex III; IV, complex IV; LDHA, lactate
    dehydrogenase A; LDHB, lactate dehydrogenase B; mTOR, mammalian target of rapamycin;
    NQO1, NAD(P)H quinone dehydrogenase; PDH, pyruvate dehydrogenase complex; PDK1,
    pyruvate dehydrogenase kinase 1; PHGDH, 3-phosphoglycerate dehydrogenase; PPP,
    pentose phosphate pathway; R5P, ribose 5-phosphate; ROS, reactive oxygen species;
    SOD2, superoxide dismutase 2; SSP, serine synthesis pathway; TCA, tricarboxylic
    acid cycle; V, complex V; xCT, glutamate/cysteine xCT antiporter.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HK2
  - KCNA5
  - KIF2A
  - KLK2
  - HOOK2
  - MTOR
  - SOD2
  - SOD2-OT1
  - H6PD
  - PHGDH
  - PDP1
  - DLAT
  - DLD
  - PDHA1
  - PDHA2
  - PDHB
  - PDHX
  - HLA-DQA2
  - LDHA
  - PDK1
  - PDK2
  - PDK3
  - PDK4
  - PDPK1
  - GCLC
  - SLC7A11
  - GLS
  - GLS2
  - ATP8A2
  - BRAF
  - LDHB
  - FASN
  - ESRRA
  - TES
  - Cisplatin
  - Glucose
  - Serine
  - Pyruvate
  - DCA
  - Lactate
  - Glutathione
  - Acetyl-CoA
  - Mevalonate
  - Riluzole
  - Simvastatin
  - Cystine
  - Glutamate
  - TCA
  - Glutamine
  - Dicoumarol
  - BSO
  - Orlistat
  - Fatty Acids
  - O Glutamine
  - ATP
  - myeloma
  - ovarian cancer
  - breast cancer
  - melanoma
---
